SIM0609 / Simcere - LARVOL DELTA

Preclinical development of SCR-A008: A CDH17-targeted ADC for gastrointestinal cancer (AACR 2025) - "These findings suggest that SCR-A008 is a potential Best-in-Class therapeutic drug for CDH17-positive solid tumor."

ADC • Preclinical • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Liver Cancer • Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • CDH17

A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=232 | Recruiting | Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

First-in-human • New P1 trial • Colorectal Cancer • Oncology • Solid Tumor

SIM0609, a CDH17 Antibody-Drug Conjugate (ADC)…,has obtained the Clinical Trial Approval issued by the National Medical Products Administration of China, which is intended for commencing the clinical trial for advanced solid tumors (HKEXnews)

New trial • Solid Tumor